^
    5ms
    Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (clinicaltrials.gov)
    P1, N=55, Recruiting, Orano Med LLC | N=30 --> 55 | Trial completion date: Jan 2025 --> Aug 2027 | Trial primary completion date: Aug 2024 --> Aug 2026
    Enrollment change • Trial completion date • Trial primary completion date
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    212Pb-DOTAM-GRPR1
    2years
    Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (clinicaltrials.gov)
    P1, N=30, Recruiting, Orano Med LLC | N=50 --> 30
    Enrollment change • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    212Pb-DOTAM-GRPR1
    almost3years
    Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (clinicaltrials.gov)
    P1, N=50, Recruiting, Orano Med LLC | Not yet recruiting --> Recruiting | Initiation date: May 2022 --> Dec 2022
    Enrollment open • Trial initiation date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    212Pb-DOTAM-GRPR1
    over3years
    Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors (clinicaltrials.gov)
    P1, N=50, Not yet recruiting, Orano Med LLC
    New P1 trial
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 negative
    |
    212Pb-DOTAM-GRPR1